Revvity (RVTY)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$130.22-0.31%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Primary pillar broken — organic revenue growth of 3%-4% in 2026: Q2 FY26 rev +1.0% vs 3.0% target.
Revvity grows revenue about 3%-4% a year. It targets adjusted EPS near $5.25 in 2026. The company has beaten earnings estimates recently. Its valuation is below peers, offering room to trade higher.
Revenue growth could slow below 2%. EPS growth may stall or decline. The divestiture of its China Immunodiagnostics business could reduce revenue by 6%.
The price is about 7% above our fair value near $104, reflecting roughly 2% revenue growth. Our fair value is 10% below the Street median, which is more optimistic on growth.
Breaks if: adjusted EPS falls below $5.00 in FY26
Breaks if: divestiture delays or revenue loss exceeds 6% of 2025 revenue
Complete the divestiture of the Immunodiagnostics business in China, expected in 2027 after regulatory approvals.
Stated as a priority in 2 of last 2 quarters. Management announced the strategic divestiture of the China Immunodiagnostics business, which accounted for approximately 6% of 2025 revenue. The divestiture is expected to complete in 2027 after regulatory approvals. The company has provided pro forma financials excluding this business, indicating active execution on this priority.
“Sets forth pro forma financials after giving effect to probable sale of Immunodiagnostics business in China.”
“Announces intention to divest China Immunodiagnostics business; definitive agreement expected in Q2 2026; completion in 2027.”
Breaks if: organic revenue growth falls below 2% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is a stable growth play with a focus on consistent revenue and earnings growth. The current thesis state reflects a medium confidence level, supported by strong recent financial performance and stable management.
The valuation is considered expensive compared to peers, with expectations that may be slightly optimistic. The market seems to be pricing in continued strong performance, but there is a notable expectations gap.
Fundamentals are likely to show moderate growth, as management aims for organic revenue growth of 3%-4% for 2026. Recent earnings results have been strong, but there is a risk of missing future targets given the historical context.
The thesis hinges on management's ability to execute on their growth targets and the overall health of the healthcare sector. Key factors include the performance of sector bellwethers and any potential guidance cuts from RVTY.
Overall, RVTY's trajectory appears stable, but investors should remain cautious of potential risks. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this view. Revvity reported Q2 revenue of $729.68 million, exceeding expectations. Adjusted EPS was $1.41, higher than the forecast of $1.21. Stifel raised its estimate for Revvity shares to $110. This estimate increase reflects improved analyst expectations for the stock.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.